We provide our clients with comprehensive advice and guidance on all stages of Paragraph IV disputes, including strategic assessment of Abbreviated New Drug Applications (ANDAs), Paragraph IV opinions and notice letters, litigation, appeals and settlements.
Recognized as the Top 50 Performing Law Firm and Top 100 Most Active Law Firm representing defendants in Hatch-Waxman litigation in the 2020 Abbreviated New Drug Application (ANDA) Litigation Intelligence Report released by intellectual property analytics company Patexia, our patent litigators have strong technical and scientific backgrounds needed to succeed in litigation and settlements for our generic pharmaceutical clients.
Our patent litigators, many of whom have strong technical and scientific backgrounds, have represented our generic pharmaceutical clients in over 30 Hatch-Waxman matters, with numerous successes in litigation and settlements for our clients.